Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

NEW HAVEN, Conn., March 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VIOND) today announced financial results for the fourth quarter and year-end of 2007.

The Company reported a net loss of $34.0 million, or $5.05 per share, for the year ended December 31, 2007, compared with a net loss of $25.3 million, or $3.83 per share, for 2006. Weighted-average common shares outstanding for the years ended December 31, 2007 and December 31, 2006 were 6.7 million and 6.6 million, respectively. The net loss increased in 2007 by $8.7 million over the previous year, primarily as a result of non-cash expenses including: (i) $5.1 million of interest expense related to Vion's convertible senior notes and (ii) $2.5 million of higher stock-based compensation expense. In addition, costs associated with clinical, regulatory and pre-commercialization activities for the Company's lead product candidate, Cloretazine(R) (VNP40101M) increased year-over-year.

The Company reported ending the year with $61.1 million in cash and cash equivalents.

Alan Kessman, Chief Executive Officer, commented, "Based on our current operating plan, we are funded through the third quarter of 2009. We continue to make progress on preparing a New Drug Application for our lead anticancer agent Cloretazine(R) (VNP40101M) for filing with the U.S. Food and Drug Administration in 2008."

A net loss of $8.2 million, or $1.18 per share, was reported for the fourth quarter of 2007, compared with a net loss of $6.1 million, or $0.92 per share, for the same period in 2006. Weighted-average common shares outstanding for the three months ended December 31, 2007 and 2006 were 6.9 million and 6.6 million, respectively.

On February 20, 2008, the Co
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... committed to the fostering and monetization of intellectual ... VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix ... 3:13-cv-03496-M, both in the United States District Court ... . On November 21, ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... Colo. (PRWEB) November 21, 2014 ... proprietary cloud based analytics and scientific testing methodologies relating ... commitment for a $750,000 line of credit from an ... extremely pleased to have secured this commitment from one ... Executive Officer of CannLabs. “This capital will help accelerate ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by ... Glass, Plastic), by Application [GC, LC (HPLC, UHPLC, ... 2018” analyses and studies the major market drivers, ... Asia, and Rest of the World. , Browse ... through 135 pages and in-depth TOC on “Chiral ...
Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2CannLabs Secures $750,000 Line Of Credit 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... JOLLA, Calif., July 14 Synthetic Genomics Inc. (SGI), ... address a variety of global challenges including energy and ... agreement with ExxonMobil Research and Engineering Company (EMRE) ... , , As part ...
... ... by Dr. Charles Stewart at DualAlign LLC is breaking new ground in medical imaging, ... stitch images even if the originals were taken from different cameras, of varying scale, ... ...
... , , ARLINGTON, Va., July 13 ... from GPhA President and CEO Kathleen Jaeger on the Senate HELP ... "While we are extremely disappointed that the Committee action could ... we will continue to fight in the House to ensure that ...
Cached Biology Technology:Synthetic Genomics Inc. and ExxonMobil Research and Engineering Company Sign Exclusive, Multi-Year Agreement to Develop Next Generation Biofuels Using Photosynthetic Algae 2Synthetic Genomics Inc. and ExxonMobil Research and Engineering Company Sign Exclusive, Multi-Year Agreement to Develop Next Generation Biofuels Using Photosynthetic Algae 3Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries 2Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries 3GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients 2
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/5/2014)... dedicated his career to understanding the Earth,s climate ... , As deputy director and regional climatologist for ... Research Institute, Redmond has more than three decades ... of climate data to the general public. , ... Francisco on December 15-19, 2014 the American Geophysical ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... the course of human evolution. A human skull discovered over ... Eastern Cape Province of South Africa, is one such fossil. ... Frederick Grine of the Departments of Anthropology and Anatomical Sciences ... Science magazine has dated the skull to 36,000 years ago. ...
... not afraid of heights, they're voracious, and Dr. Spencer Behmer ... oak trees or on your house. , They're post ... wants to research their life cycle and behavior. ... Until recently, most Texans hadn't. , "I didn't ...
... ensure that no two people are exactly alike, and ... Now, researchers have the tools and the knowledge to ... enabling them to create more effective therapies for individual ... the American Association for Cancer Research, researchers present new ...
Cached Biology News:Hofmeyr skull supports the 'Out of Africa' theory 2Hofmeyr skull supports the 'Out of Africa' theory 3Post oak grasshoppers emerging 2Genes and biomarkers that allow doctors to choose the right therapy for the right patient 2Genes and biomarkers that allow doctors to choose the right therapy for the right patient 3Genes and biomarkers that allow doctors to choose the right therapy for the right patient 4Genes and biomarkers that allow doctors to choose the right therapy for the right patient 5Genes and biomarkers that allow doctors to choose the right therapy for the right patient 6